Photo: Jan Chlebik for the ICR
The Alife2 study is investigating whether anti-coagulant (blood-thinning) treatment reduces the risk of miscarriage in women with two or more (unexplained) miscarriages and inherited thrombophilia – a blood-clotting problem.
The PRISM trial is an important research study which looked at whether progesterone could prevent miscarriage in women with early pregnancy bleeding.
The RESPONSE trial tested a new medication, called NT100, in women with unexplained repeated miscarriages.
The TABLET trial is an important research study which looked at the role of thyroid antibodies in women with unexplained miscarriage.
A clear result – Progesterone supplements in the first trimester of pregnancy do NOT improve outcomes in women with a history of unexplained recurrent miscarriages.
Sarah Bailey describes a different type of research study which is looking at trying to improve the psychological wellbeing of women who have suffered recurrent miscarriage.
Ruth interviews Professor Arri Coomarasamy, Consultant Gynaecologist and Sub-specialist in Reproductive Medicine and Surgery at Birmingham Women’s Hospital.
The Miscarriage Association (M.A.) has been involved in a partnership to decide which areas are the highest priority for miscarriage research. The project was run by the James Lind Alliance and involved other charities, healthcare professionals and researchers, as well as the M.A.. On this page you will find a short summary of the results.